Obesity: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GLP-1 169
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT07553299· Verdiva Bio Dev Limited· Updated 13 Oct 2026

  “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”Registry text, quoted unchanged. Source

• Terminated

  RESCUE: Discontinuation of GLP-1

  NCT07190794· Boston Scientific Corporation· Updated 24 Jul 2026

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change

  NCT07097974· TCI Co., Ltd.· Updated 13 May 2026

  “based on an overall assessment of feasibility and strategic considerations”Registry text, quoted unchanged. Source

• Suspended

  Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Updated 30 Mar 2026

  “Study pending amendment”Registry text, quoted unchanged. Source

• Withdrawn

  The Effects of Semaglutide on Body Composition and Performance in Military Personnel

  NCT06468748· United States Army Research Institute of Environmental Medicine· Updated 19 Dec 2025

  “lack of funding”Registry text, quoted unchanged. Source

• Terminated

  A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

  NCT06000891· Zealand Pharma· Updated 25 Apr 2025

  “Decision by Sponsor; LSLV was completed on 21-Mar-2025 as planned.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

  NCT06515418· BioAge Labs, Inc.· Updated 13 Mar 2025

  “Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

  NCT04885634· Axel Brandes· Updated 3 Nov 2023

  “Not received funding.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  NCT07830329· Regeneron Pharmaceuticals· Source

• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

  NCT06162715· Vanderbilt University Medical Center· Source

• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· AstraZeneca· Source

• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Amgen· Source

• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Regeneron Pharmaceuticals· Source

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Pfizer· Source

• A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Pfizer· Source

• A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Pfizer· Source

• A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

  NCT07915609· Pfizer· Source

• A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 20
• Organoids 10
• Mendelian Randomization Analysis 179
• CRISPR-Cas Systems 7
• Gene Expression Profiling 143
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 126
• Metabolomics 190
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 255
• Machine Learning 155
• Deep Learning 20
• Cohort Studies 1009
• Genome-Wide Association Study 201

• Development of a Multimodal Obstructive Sleep Apnea Diagnostic Prediction Model Using Two-Dimensional Facial Images and Clinical Data.

  IEEE J Biomed Health Inform, Oct 2026

• Correlation of whole-body fat content and its distribution with lumbar fat content under different age, gender and BMI conditions: quantitative analysis of MRI based on deep learning.

  BMC Musculoskelet Disord, Jul 2026

• Deep progressive learning reconstruction for fast and low-dose whole-body PET scans in an integrated PET/MR system.

  BMC Med Imaging, Jul 2026

• Deep learning analysis of ECGs detects Cardiovascular-Kidney-Metabolic syndrome burden in people with diabetes: a report from the Silesia Diabetes-Heart Project.

  Cardiovasc Diabetol, Jun 2026

• A deep-learning framework reveals whole-body perturbations at cell level.

  Nature, May 2026

• Design and validation of renal stone detection using multi-architecture feature extraction with deep sequential learning model on axial computed tomography images.

  Sci Rep, May 2026

• Incremental value of deep learning denoising in low-dose coronary CT angiography in predominantly obese patients.

  Eur J Radiol, Apr 2026

• Health Prediction Using Hybrid Deep Learning Models: A Transparent and Interpretable Approach.

  Int J Health Plann Manage, Apr 2026

• Machine and Deep Learning Models for Preoperative Prediction of Suboptimal Clinical Response One Year after Metabolic Bariatric Surgery: Findings from the Tehran Obesity Treatment Study.

  Obes Surg, Mar 2026

• Ameliorative effect of Rhus verniciflua Stokes on high-fat diet-induced obesity and advanced analysis with machine learning and deep learning-based network pharmacology.

  Life Sci, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.